Author Archives: Warren Woessner

Cybersource Corp. v. Retail Decisions, Inc.

Posted on August 19, 2011 by Warren Woessner

In recent posts, I have worried, then warned, the Fed. Cir. holding that the Myriad “analyzing” or “comparing” diagnostic claims were invalid as abstract ideas, would cloud the IP future of “modern” claims to personalized medicine (see posts of … Continue reading →

Wegner Paper Probes Myriad Decisions Flaws

Posted on August 2, 2011 by Warren Woessner

Prof. Hal Wegner goes for the jugular with his analysis of some of the flaws in the legal reasoning behind the holding in the recent AMC v. Myriad decision. [See my post of July 31st 2011 on the decision]. (Prof. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged biotechnology, biotechnology news, Chakrabarty, Federal Circuit, Funk Brothers, hal wegner, intellectual property, ip, Myriad, Myriad lawsuit, Patent Law, patents, Warren Woessner | Leave a comment

AMC v. Myriad – “Laws of Nature” Exception Does Not Include Isolated DNA

Posted on July 31, 2011 by Warren Woessner

As noted in my last “flash” post, a divided three-judge Fed. Cir. panel (Judges Lourie, Bryson and Moore) issued an opinion holding that the isolated DNA sequences and the drug-screening method claimed by Myriad are patentable subject matter, not natural … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged ACLU, biotechnology, biotechnology law, biotechnology news, DNA, Federal Circuit, intellectual property, ip, Myriad, Myriad lawsuit, Patent Law, patents, Pharmaceutical law, USPTO, Warren Woessner | 2 Comments

Divided Panel Finds DNA Molecules Patentable – Cancer Screening Claims Too Abstract

Posted on July 29, 2011 by Warren Woessner

Today a divided Fed. Cir. panel of Judges Lourie, Moore and Bryson – Lourie writing for the “majority” – reversed the district court judge, in AMP v. Myriad, holding that isolated DNA sequences are patent-eligible subject matter and not natural … Continue reading →